Given the growing list of gene mutations of prognostic implication in AML, including recently identified mutations in DNMT3A, TET2, and ASXL1, a good surrogate marker can be a more global one, such as the S17 signature, which is correlated to several markers, in addition to its independent impact. The gene discussed is TET2; the disease is acute myeloid leukemia.